Numerous studies were aimed at selecting inhibitors, including aptamers, for EGFR because it is a relevant feature in primary GBM (it is overexpressed in 60% of tumors) and its mutation correlates with poor prognosis and tumor aggressiveness [59,60]. Here, EGFR is linked to glioblastoma.